Open-label prospective trial to study efficacy, safety and tolerability of intravenous
immunoglobulin (IVIG) once monthly for 6 months in children and adolescents with PANS. Number
of subjects: 10. Age range: 4-17 years.
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a recently defined research
diagnosis describing an abrupt, dramatic onset of neuropsychiatric symptoms including
obsessions/compulsions and/or food restriction in children. Immunologic mechanisms are
suspected, but treatment trials are few.